ClinicalTrials.gg
RecruitingNCT06403267Updated Jul 15, 2025

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

A Phase 2 interventional study of NoNO-42 in Acute Ischemic Stroke, sponsored by NoNO Inc.. Recruiting at 9 sites in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by NoNO Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 117 studies in Ischemic Stroke with a site in Canada — 32 open to participants now, 39 under way, 9 of them phase 3. Ischemic Stroke · Canada.

Planned enrollment
33rd of 90
600 · median 275
Started
2024
with 7 others
Phase 2
17 of 117
5 open now
Primary completion
2026-12
later than 11 of 38 live
Registered
100th of 117
by date
Lead sponsor
3 of 117
NoNO Inc.

Among the 117 studies in Ischemic Stroke with a site in Canada, this one is the 33rd largest by planned enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2024, is one of 17 in phase 2, reaches primary completion later than 11 of the 38 other live ones, and was the 100th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 117 studies in Ischemic Stroke with a site in Canada are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Ischemic Stroke with a site in Canada, or all of them as a file.
02

Study summary

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).

This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.

A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.

Read the detailed description

Because AIS is a medical emergency, the trial is designed to enable the administration of standard-of-care treatments in order to save the life of the person concerned, restore good health and alleviate suffering.

A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well. Randomization will be 1:1 drug/placebo. Randomization will be stratified by large vessel occlusion (LVO) (yes/no) and a minimization algorithm to minimize the contribution of imbalances in baseline factors (age, sex, baseline NIHSS score). The design is adaptive with prospective rules for adaptive enrichment, in which enrollment may be restricted to participants without an LVO. LVO is defined as an occlusion of the intracranial ICA, M1 or proximal M2.

Randomized participants will receive/received an intravenous thrombolytic and be allocated to:

  • the investigational group, a single, 2.6 mg/kg (up to a maximum of 300 mg) 20-minute intravenous dose of NoNO-42, with a target start time of less than 10 minutes from randomization or
  • the control group, no trial specific intervention.

Day 90: All participants will be followed for 90 days (or until death if prior to 90 days) for efficacy and 30 days for safety. The end of the trial is defined as the date that all participants have completed their Day 90 contact.

1-Year follow Up: participants who completed the trial to Day 90 may be followed at 1 year for long-term efficacy.

One database lock and corresponding report for the trial to Day 90 and a separate database lock and analysis for the 1-year follow up are planned.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Thrombolysis, Endovascular thrombectomy
  • Reperfusion
  • Neuroprotection
  • Neuroprotectant
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed or suspected acute ischemic stroke (AIS) selected for intravenous thrombolysis.
  2. Onset (last-known-well) time to randomization time within 4.5 hours.
  3. Ages ≥ 18 to ≤ 90 years.
  4. Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) >5.
  5. Confirmed or suspected symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted.
  6. Pre-stroke independent functional status in activities of daily living as judged by the enrolling physician. Patient must be living without requiring nursing care.
  7. Consent process completed as per national laws and regulation and the applicable ethics committee requirements.

Exclusion criteria

Exclusion Criteria:

  1. Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging.
  2. Any intracranial hemorrhage on qualifying imaging.
  3. Unlikely to initiate study drug administration before arterial puncture in those selected for EVT.
  4. Known/suspected pregnancy and/or lactation.
  5. Systolic blood pressure \< 90 mmHg
  6. Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial.

8) Severe comorbid illness with less than 90 days, or likely to prevent completing 90-day follow-up.

9) Long term care facility resident or prisoner 10) Participation in another clinical trial outside of the ACT-GLOBAL platform investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding trial enrolment.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    NoNO-42

    Randomized participants will be given a single, 2.6 mg/kg 20-minute intravenous dose of NoNO-42 with a target start time of less than 10 minutes from randomization.

    Drug: NoNO-42

  • No intervention
    Control

Interventions

  • a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.

06

What researchers measure

Primary outcomes

  1. Reducing global disability in participants with acute ischemic stroke (AIS)

    The primary outcome is the mRS at Day 90. The primary analysis of the primary outcome will be a "shift" analysis, which is an ordinal analysis across the mRS scale. The primary estimand is odds-ratio for a better outcome on the mRS scale for NoNO-42 compared to control.

    Time frame: 90 days from intervention

Secondary outcomes

  1. Improving excellent functional outcome

    Proportion of participants with a mRS of 0-1 at Day 90

    Time frame: 90 days from intervention

  2. Reducing worsening of stroke

    Proportion of participants exhibiting a worsening of their index stroke during hospitalization. Worsening of stroke is defined as (A) progression of the index stroke or symptomatic intracranial, or symptomatic intracranial hemorrhagic within the first 7-days after randomization, supported and confirmed by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥ 4-point increase from lowest NIHSS during initial hospitalization or (B) results in death from the index stroke (i.e., index stroke is judged to be the principal cause of death) within the first 21-days after randomization.

    Time frame: 90 days from intervention

  3. Improving functional independence

    Proportion of participants with a mRS of 0-2 at Day 90.

    Time frame: 90 days from intervention

  4. Reducing mortality rate

    Proportion of participant mortality over the 90-day trial period

    Time frame: 90 days from intervention

  5. Improving health-related quality of life

    Health-related quality of life, as measured by the EQ-5D-5L at Day 90

    Time frame: 90 days from intervention

Other outcomes

  1. 1 year Follow-up

    Whenever possible, participants will be followed up to 1 year post stroke to determine the efficacy of NoNO-42 at 1 year post stroke in: • Reducing global disability in participants with acute ischemic stroke (AIS).- - proportion of participants with a shift of one or more categories to reduced functional dependence analyzed across the whole distribution of outcomes on the mRS Scale The secondary objectives are to determine the efficacy of NoNO-42 at 1 year post stroke in: * Improving excellent functional outcome - Proportion of participants with a mRS of 0-1 at 1-year. * Improving functional independence - Proportion of participants with a mRS of 0-2 at 1-year * Reducing mortality rate - Proportion of participant mortality over 1-year * Improving health-related quality of life - Health-related quality of life, as measured by the EQ-5D-5L at 1-year

    Time frame: 1 year post intervention

  2. Safety Outcome

    safety of a single 2.6 mg/kg dose of intravenous NoNO- 42 based on: * Serious adverse events (SAEs) to Day 30 and * 90-day mortality.

    Time frame: 30 and 90 days post intervention

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 26 months is close to that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 7, 2024
StartActual
Oct 2, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06403267
Lead sponsor
NoNO Inc.
Responsible party
Sponsor
First posted
May 7, 2024
Start date
Oct 2, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 15, 2025

Study contacts

Michael Tymianski, MD PhD
Contact
mtymianski@nonoinc.ca
416-583-1687
Bijoy Menon, MBBS, MD
study chair · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NONO-42

Start the discussion